OXBRYTA is a prescription medicine used for the treatment of sickle cell disease in adults and children 4 years of age and older.
It is not known if OXBRYTA is safe and effective in children with sickle cell disease below 4 years of age.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Do not take OXBRYTA if you or your child have had an allergic reaction to voxelotor or any of the ingredients in OXBRYTA. See the end of the patient leaflet for a list of the ingredients in OXBRYTA.
Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how OXBRYTA works. OXBRYTA may also affect how other medicines work and may affect the results of certain blood tests. Keep a list of all your medicines and show it to your healthcare provider.
Do not take St. John’s wort during treatment with OXBRYTA.
Serious allergic reactions. Tell your healthcare provider or get emergency medical help right away if you get:
These are not all the possible side effects of OXBRYTA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).
Keep OXBRYTA and all medicines out of the reach of children.
Oxbryta, GBT Source, GBT Source Solutions, and the GBT logo are registered trademarks of Global Blood Therapeutics, Inc. All other trademarks are the property of their respective owners.
© 2022 Global Blood Therapeutics, Inc. All Rights Reserved. P-VOX-US-00098 v7
This site is intended for residents of the United States, Puerto Rico, and US territories.MORE Back to top